Cenker Eken

Cenker Eken

Auto-generated profile, based on publicly available information

Cenker Eken

Department of Emergency Medicine, Akdeniz University School of Medicine, Antalya, Turkey

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in European Journal of Emergency Medicine
Verified
Journal Article
Closed access
CECenker Eken
Cenker Eken
MKMutlu Kartal
Mutlu Kartal
ABAyse Bacanli
Ayse Bacanli
OEOktay Eray
Oktay Eray
The Glasgow Coma Scale (GCS) is the most widely used tool for the evaluation of the level of consciousness. The Full Outline of Unresponsiveness (FOUR) Score is a new coma Scale that was developed considering the limitations of the GCS, and has been found to be useful in an intensive care setting. We aimed to compare FOUR Score and GCS in the emergency setting. All patients older than 17 years who presented with an altered level of consciousness, after any trauma to the head or with neurological complaints were included in this study. Three-month mortality, in-hospital mortality, and poor outcome using a Modified Rankin Scale (MRS) of 3-6 points were used as the primary outcome measures. A total of 185 patients were included in the study. Area under the curve (AUC) values in predicting 3-month mortality for GCS was 0.726 [P=0.0001 and 95% confidence interval (CI): 0.656-0.789] and 0.776 (P=0.0001 and 95% CI: 0.709-834) for FOUR Score. AUC in predicting hospital mortality for GCS was 0.735 (P=0.0001 and 95% CI: 0.655-0.797) and 0.788 (P=0.0001 and 95% CI: 0.722-0.844) for FOUR Score. AUC in predicting poor outcome (Modified Rankin Scale: 3-6) was 0.720 (P=0.001 and 95% CI: 0.650-784) for GCS and 0.751 (P=0.0001 and 95% CI: 0.682-0.812) for FOUR Score. The new coma Scale, FOUR Score, is not superior to the GCS. However, the combination of the eye and motor components of FOUR Score is a valuable tool that can be used instead of either the FOUR Score or GCS.

1 August 2010 in The Journal of Emergency Medicine
Verified
Journal Article
Closed access
CECenker Eken
Cenker Eken
COCem Oktay
Cem Oktay
ABAyse Bacanli
Ayse Bacanli
BGBedia Gulen
Bedia Gulen
CKCem Koparan
Cem Koparan
YCYildiray Cete
Yildiray Cete

1 March 2015 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
CECenker Eken
Cenker Eken

1 November 2016 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
BGBedia Gulen
Bedia Gulen
CECenker Eken
Cenker Eken
OKOkkes Taha Kucukdagli
Okkes Taha Kucukdagli
MSMustafa Serinken
Mustafa Serinken
AKAbdurrahim Kocyigit
Abdurrahim Kocyigit
HUHüseyin Uyarel
Hüseyin Uyarel

1 August 2015 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
AOAlten Oskay
Alten Oskay
OEOktay Eray
Oktay Eray
SDSelcan Enver Dinç
Selcan Enver Dinç
AAAlp Giray Aydın
Alp Giray Aydın
CECenker Eken
Cenker Eken

5 May 2015 in Cephalalgia
Verified
Journal Article
Closed access
FGFaruk Gungor
Faruk Gungor
KAKamil Can Akyol
Kamil Can Akyol
MKMustafa Kesapli
Mustafa Kesapli
ACAhmet Celik
Ahmet Celik
AKAdeviye Karaca
Adeviye Karaca
CECenker Eken
Cenker Eken
Migraine is a leading headache etiology that frequently presents to the emergency department (ED). In the present study, we aimed to determine the efficacy of dexketoprofen in aborting migraine headaches in the ED. This prospective, randomized, double-blind study was conducted in an ED of a tertiary care hospital using allocation concealment. Patients were allocated into two arms to receive the study drug; 50 mg dexketoprofen in 50 ml saline and 50 ml saline as placebo. Change in pain intensity was measured by the visual analog scale at baseline, both at 30 and 45 minutes after the study medication was administered. Rescue medication requirement and pain relapse were also recorded by a telephone follow-up at 48 hours. A total of 224 patients (112 in each group) were included into the final analysis. Mean age of the study participants was 37 ± 11 (SD) and 25% (n = 56) of them were male. The median pain improvement at 45 minutes for patients receiving dexketoprofen was 55 (IQR: 49 to 60) and 30 (IQR: 25 to 35) for those receiving placebo. The mean difference between the two groups at 45 minutes was 21.4 (95% CI: 14.4. to 28.5). Rescue drugs were needed in 22.3% of patients who received dexketoprofen compared to 55.4% in patients who received placebo (dif: 33.1%; 95% CI: 20% to 45%). There were no adverse events reported in either group during the study period. Intravenous dexketoprofen is superior to placebo in relieving migraine headaches in the ED. It may be a suitable therapy with minimum side effects in patients presenting with a migraine headache to the ED.